This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. Duo Hybrid has a distinct integrated design that combines multiple zones of differing mechanical properties into a single stent [3].
16, 2024 — Sahajanand Medical Technologies (SMT) recently announced the publication of the COMPARE 60/80 HBR trial results in Circulation: Cardiovascular Interventions , a journal of The American Heart Association. tim.hodson Wed, 10/16/2024 - 09:00 Oct. Led by Dr. Pieter C. and 17.1%, respectively (P=0.02 for noninferiority).
million Department of Defense grant awarded to the Georgia Institute of Technology (Georgia Tech), Yaxin Wang, PhD (seated left), O.H. However, there are shortcomings associated with LVAD implantation: complications include infection, blood clotting (thrombosis), stroke and bleeding. Through a new four-year, $7.8
3 The third‐generation iteration of the Pipeline Embolization Device (PED) incorporates Shield technology, a phosphorylcholine coating designed to reduce thrombogenicity via mimicry of native cell membranes.4 IntroductionIndications for flow diversion for the treatment of cerebral aneurysms have increased remarkably in recent years.1
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content